Publication
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerLung Small Cell Carcinomacivic_curation1.00
- drugCisplatincivic_curation1.00
- drugOlaparibcivic_curation1.00
- drugPrexasertibcivic_curation1.00
- geneCHEK1civic_curation1.00
- geneMYCcivic_curation1.00
- variantCHEK1 Overexpressioncivic_curation1.00
- variantMYC Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28490518
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CHEK1 Overexpression1 | ||||||||
| Cisplatin + Olaparib + PrexasertibCombination | Lung Small Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID4874A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexa… (full text at CIViC) PMID 28490518 · Sen et al., 2017 · Open in CIViC | civic |
| MYC Overexpression1 | ||||||||
| Cisplatin + Olaparib + PrexasertibCombination | Lung Small Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID3003A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexa… (full text at CIViC) PMID 28490518 · Sen et al., 2017 · Open in CIViC | civic |